Editas Medicine Inc
No standout activity across the feeds we track.
What this band has actually done: stocks scoring 0–25 beat the S&P 500 over the next three months 39.9% of the time, across 100,496 cases since 2015. That is below a coin flip — and so is every other band, because the median stock loses to a cap-weighted index. How we measured this
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research…
| Trade date | Member | Chamber | Action | Amount |
|---|---|---|---|---|
| 2023-04-10 | Daniel S. Goldman · D-NY | House | Sold | $1,001 - $15,000 |
| 2021-04-14 | Donald S. Beyer, Jr. · D-VA | House | Sold | $1,001 - $15,000 |
| 2021-03-02 | Donald S. Beyer, Jr. · D-VA | House | Sold | $1,001 - $15,000 |
| 2020-11-17 | Donald S. Beyer, Jr. · D-VA | House | Bought | $1,001 - $15,000 |
| 2020-05-01 | Donald S. Beyer, Jr. · D-VA | House | Sold | $1,001 - $15,000 |
| 2020-04-27 | Donald S. Beyer, Jr. · D-VA | House | Sold | $1,001 - $15,000 |
| 2020-01-27 | Donald S. Beyer, Jr. · D-VA | House | Bought | $1,001 - $15,000 |
| 2020-01-09 | Donald S. Beyer, Jr. · D-VA | House | Bought | $1,001 - $15,000 |
| 2019-12-23 | Donald S. Beyer, Jr. · D-VA | House | Bought | $1,001 - $15,000 |
| 2019-06-04 | Donna E. Shalala · D-FL | House | Sold | $1,001 - $15,000 |
Show the other 3
| Trade date | Member | Chamber | Action | Amount |
|---|---|---|---|---|
| 2019-03-06 | Donna E. Shalala · D-FL | House | Bought | $1,001 - $15,000 |
| 2019-02-04 | James M. Inhofe · R-OK | Senate | Sold | $15,001 - $50,000 |
| 2017-10-19 | James M. Inhofe · R-OK | Senate | Bought | $15,001 - $50,000 |
Markers sit on the transaction date the member disclosed, snapped to the nearest close on the chart. They are not the date the public found out — that came later, and the gap is its own page. Every marker is listed by name in the table above.